Contrasting CONMED (CNMD) and Cytori Therapeutics (CYTX)

CONMED (NASDAQ: CNMD) and Cytori Therapeutics (NASDAQ:CYTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Valuation & Earnings

This table compares CONMED and Cytori Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CONMED $796.39 million 2.11 $55.48 million $1.97 30.50
Cytori Therapeutics $4.66 million 2.34 -$22.04 million ($0.90) -0.34

CONMED has higher revenue and earnings than Cytori Therapeutics. Cytori Therapeutics is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.


This table compares CONMED and Cytori Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CONMED 6.97% 9.15% 3.97%
Cytori Therapeutics -367.33% -228.21% -69.19%


CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.3%. Cytori Therapeutics does not pay a dividend. CONMED pays out 40.6% of its earnings in the form of a dividend.

Institutional and Insider Ownership

98.5% of CONMED shares are owned by institutional investors. Comparatively, 10.8% of Cytori Therapeutics shares are owned by institutional investors. 2.6% of CONMED shares are owned by company insiders. Comparatively, 1.9% of Cytori Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

CONMED has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 3.56, suggesting that its share price is 256% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for CONMED and Cytori Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CONMED 0 3 1 0 2.25
Cytori Therapeutics 0 1 1 0 2.50

CONMED currently has a consensus price target of $55.00, indicating a potential downside of 8.47%. Cytori Therapeutics has a consensus price target of $3.65, indicating a potential upside of 1,077.42%. Given Cytori Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Cytori Therapeutics is more favorable than CONMED.


CONMED beats Cytori Therapeutics on 10 of the 15 factors compared between the two stocks.

CONMED Company Profile

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company’s product lines consist of orthopedic surgery, general surgery and surgical visualization. As of December 31, 2016, the Company’s products are distributed domestically directly to over 6,000 hospitals, surgery centers and other healthcare institutions, as well as through medical specialty distributors. The Company’s orthopedic surgery product lines include sports medicine, powered surgical instruments, and sports biologics and tissue. These products are marketed under a range of brands, including Hall, CONMED Linvatec, Concept and Shutt.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with's FREE daily email newsletter.

Leave a Reply